Ipamorelin CAS: 170851-70-4

CAS NO: 170851-70-4
Ipamorelin
Chemical Name: Ipamorelin
Molecular Formula: C38H49N9O5
Formula Weight: 711.85
CAS No.: 170851-70-4
Description Review
Description

Ipamorelin is a synthetic peptide that stimulates the production of growth hormone (GH) in the body. CAS: 170851-70-4

Chemical Name: (SHE)d-Ala-d-2-Nal-Ala-Trp-d-Phe-Lys-NH2 acetate salt

Molecular Formula: C38H49N9O5

Formula Weight: 711.85 g/mol

CAS No: 170851-70-4

Top Searched Keywords on Google and Synonyms on google:

Ipamorelin, CAS: 170851-70-4, Ipamorelin benefits, Ipamorelin dosage, Ipamorelin side effects, Ipamorelin safety.

Health benefits:

Ipamorelin works by stimulating the production and release of growth hormone (GH) in the body. This can lead to several potential benefits for users, including an increase in muscle mass, a decrease in body fat, improved bone density, and an overall improvement in physical performance and recovery.

Other potential benefits of Ipamorelin include improved immune function, increased energy levels, and an overall improvement in quality of life.

Potential Effects:

The effects of Ipamorelin can vary depending on the individual and the dosage used. However, some commonly reported effects include:

  • Increased muscle mass
  • Decreased body fat
  • Improved bone density
  • Improved physical performance and recovery
  • Improved immune function
  • Increased energy levels
  • Improvement in quality of life

Mechanisms:

Ipamorelin works by binding to the growth hormone secretagogue receptor (GHSR) in the hypothalamus, which stimulates the production and release of growth hormone (GH) in the body.

Once released into the bloodstream, growth hormone has several anabolic effects on the body, including the stimulation of protein synthesis and the promotion of lipolysis (fat breakdown).

Ipamorelin also has a powerful effect on the production of insulin-like growth factor-1 (IGF-1), a protein that is involved in the growth and repair of cells throughout the body.

Safety:

While Ipamorelin is generally considered safe when used as directed, there are some potential risks associated with the drug.

One of the main risks of Ipamorelin is the potential for overstimulation of the pituitary gland, which can lead to excessive growth hormone secretion and an increased risk of side effects.

Additionally, some users may experience side effects such as headaches, flushing, and nausea. Long-term use of Ipamorelin may also increase the risk of certain types of cancer, though more research is needed to fully understand this potential risk.

Side-Effects:

The side effects of Ipamorelin can vary depending on the individual and the dosage used. Some commonly reported side effects include:

  • Headaches
  • Flushing
  • Nausea
  • Vomiting
  • Swelling and pain at injection site
  • Increased blood pressure
  • Accelerated heart rate

More serious side effects of Ipamorelin are rare but can include anaphylaxis, a severe and potentially life-threatening allergic reaction.

Dosage information:

The appropriate dosage of Ipamorelin may vary depending on individual factors such as age, gender, and body weight. In general, users are advised to start with a low dose and gradually increase over time to minimize the risk of side effects.

The recommended starting dose of Ipamorelin is usually around 100-200 micrograms per day, though this may vary depending on individual factors. Users are advised to consult with a healthcare provider or experienced user before starting Ipamorelin to determine the appropriate dosage and to discuss any potential risks or side effects.

In conclusion, Ipamorelin has potential benefits for users, including an increase in muscle mass, a decrease in body fat, improved bone density, and an overall improvement in physical performance and recovery. However, users should be aware of the potential risks and side effects associated with the drug and always use it as directed. It's also important to speak with a healthcare provider or experienced user before starting Ipamorelin to determine the appropriate dosage and to discuss any potential risks or side effects.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code